Initial data show non-inferiority to Eylea in diabetic macular edema with reduced frequency dosing but not superiority. Even so, market dynamics suggest it could still carve out blockbuster sales.
Top-line data for two identical Phase III studies of faricimab, Roche Holding AG’s novel bispecific antibody product for retinal diseases, suggest it is no better than Bayer AG’s Eylea but still likely to prove a thorn in the side of Novartis AG’s newcomer Beovu.
The two trials – YOSEMITE and RHINE – in a total of 1,891 patients with diabetic macula edema (DME) both...
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
